AZD8186, a potent and selective inhibitor of PI3Kb/d, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

J. S. de Bono,A. Hansen,A. D. Choudhury,N. Cook, E. I. Heath,C. Higano, M. Linch,J. Martin-Liberal,D. E. Rathkopf,K. B. Wisinski,S. Barry,E. de Bruin,W. Brugger, S. Colebrook,T. Klinowska, M. Moschetta, P. G. S. Mortimer,L. L. Siu, G. Shapiro

Annals of Oncology(2018)

引用 6|浏览39
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要